

Anne Genevive Marcelin

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/9483511/anne-genevieve-marcelin-publications-by-year.pdf>
Version: 2024-04-09

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

362 papers	9,166 citations	49 h-index	77 g-index
387 ext. papers	10,571 ext. citations	6.1 avg, IF	5.75 L-index

#	Paper	IF	Citations
362	Echocardiography and renin-aldosterone interplay as predictors of death in COVID-19.. <i>Archives of Cardiovascular Diseases</i> , 2022 , 115, 96-96	2.7	
361	Immune Reconstitution Inflammatory Syndrome Associated Kaposi Sarcoma.. <i>Cancers</i> , 2022 , 14,	6.6	1
360	Outcome of very high-risk patients treated by Sotrovimab for mild-to-moderate COVID-19 Omicron, a prospective cohort study (the ANRS 0003S CoCoPrev study).. <i>Journal of Infection</i> , 2022 ,	18.9	0
359	A New Topical Candidate in Acne Treatment: Characterization of the Meclozine Hydrochloride as an Anti-Inflammatory Compound from In Vitro to a Preliminary Clinical Study. <i>Biomedicines</i> , 2022 , 10, 931	4.8	
358	Memory CD4+ T-Cell Lymphocytic Angiopathy in Fatal Forms of COVID-19 Pulmonary Infection.. <i>Frontiers in Immunology</i> , 2022 , 13, 844727	8.4	1
357	Compassionate Use of Hydroxychloroquine in Clinical Practice for Patients With Mild to Severe COVID-19 in a French University Hospital. <i>Clinical Infectious Diseases</i> , 2021 , 73, e4064-e4072	11.6	34
356	XAV-19, a Swine Glyco-Humanized Polyclonal Antibody Against SARS-CoV-2 Spike Receptor-Binding Domain, Targets Multiple Epitopes and Broadly Neutralizes Variants. <i>Frontiers in Immunology</i> , 2021 , 12, 761250	8.4	3
355	Emerging RNA-Dependent RNA Polymerase Mutation in a Remdesivir-Treated B-cell Immunodeficient Patient With Protracted Coronavirus Disease 2019. <i>Clinical Infectious Diseases</i> , 2021 , 73, e1762-e1765	11.6	47
354	Low level of baseline resistance in recently HCV-infected men who have sex with men with high-risk behaviours. <i>Journal of Global Antimicrobial Resistance</i> , 2021 , 24, 311-315	3.4	
353	No difference in HIV-1 integrase inhibitor resistance between CSF and blood compartments. <i>Journal of Antimicrobial Chemotherapy</i> , 2021 , 76, 1553-1557	5.1	0
352	Performance of 30 commercial SARS-CoV-2 serology assays in testing symptomatic COVID-19 patients. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2021 , 40, 2235-2241	5.3	2
351	Poppers, by Inducing HHV-8 Virion Production, Can Act as a Promoter for HHV-8 Transmission in Men Who Have Sex With Men. <i>Open Forum Infectious Diseases</i> , 2021 , 8, ofab166	1	1
350	Intermittent two-drug antiretroviral therapies maintain long-term viral suppression in real life in highly experienced HIV-infected patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2021 , 76, 1893-1897	5.1	
349	Presence of HIV-1 G-to-A mutations linked to APOBEC editing is more prevalent in non-B HIV-1 subtypes and is associated with lower HIV-1 reservoir. <i>Journal of Antimicrobial Chemotherapy</i> , 2021 , 76, 2148-2152	5.1	1
348	Prevalence of genotypic baseline risk factors for cabotegravir + rilpivirine failure among ARV-naïve patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2021 , 76, 2983-2987	5.1	0
347	Neutralization heterogeneity of United Kingdom and South-African SARS-CoV-2 variants in BNT162b2-vaccinated or convalescent COVID-19 healthcare workers. <i>Clinical Infectious Diseases</i> , 2021 ,	11.6	4
346	Poor Antibody Response after Two Doses of SARS-CoV-2 vaccine in Transplant Recipients. <i>Clinical Infectious Diseases</i> , 2021 ,	11.6	20

345	Distinct cytokine profiles associated with COVID-19 severity and mortality. <i>Journal of Allergy and Clinical Immunology</i> , 2021 , 147, 2098-2107	11.5	18
344	Interpretation of SARS-CoV-2 replication according to RT-PCR crossing threshold value. <i>Clinical Microbiology and Infection</i> , 2021 , 27, 1056-1057	9.5	4
343	The 501Y.V2 SARS-CoV-2 variant has an intermediate viral load between the 501Y.V1 and the historical variants in nasopharyngeal samples from newly diagnosed COVID-19 patients. <i>Journal of Infection</i> , 2021 , 83, 119-145	18.9	14
342	Occurrence of Invasive Pulmonary Fungal Infections in Patients with Severe COVID-19 Admitted to the ICU. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021 , 203, 307-317	10.2	66
341	Antiphospholipid antibodies and thrombotic events in COVID-19 patients hospitalized in medicine ward. <i>Autoimmunity Reviews</i> , 2021 , 20, 102729	13.6	11
340	Co-infection of SARS-CoV-2 with other respiratory viruses and performance of lower respiratory tract samples for the diagnosis of COVID-19. <i>International Journal of Infectious Diseases</i> , 2021 , 102, 10-13	10.5	23
339	Once-daily etravirine/raltegravir (400/800 mg q24h) dual therapy maintains viral suppression over 48 weeks in HIV-infected patients switching from a twice-daily etravirine/raltegravir (200/400 mg q12h) regimen. <i>Journal of Antimicrobial Chemotherapy</i> , 2021 , 76, 477-481	5.1	
338	In Silico Investigation of the New UK (B.1.1.7) and South African (501Y.V2) SARS-CoV-2 Variants with a Focus at the ACE2-Spike RBD Interface. <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3	54
337	Rapid decline of neutralizing antibodies against SARS-CoV-2 among infected healthcare workers. <i>Nature Communications</i> , 2021 , 12, 844	17.4	81
336	Prevalence of cervical HPV infection, sexually transmitted infections and associated antimicrobial resistance in women attending cervical cancer screening in Mali. <i>International Journal of Infectious Diseases</i> , 2021 , 108, 610-616	10.5	2
335	Factors associated with the emergence of integrase resistance mutations in patients failing dual or triple integrase inhibitor-based regimens in a French national survey. <i>Journal of Antimicrobial Chemotherapy</i> , 2021 , 76, 2400-2406	5.1	0
334	Anti-CD20 therapies decrease humoral immune response to SARS-CoV-2 in patients with multiple sclerosis or neuromyelitis optica spectrum disorders. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2021 ,	5.5	25
333	Seroprevalence and molecular diversity of Human Herpesvirus 8 among people living with HIV in Brazzaville, Congo. <i>Scientific Reports</i> , 2021 , 11, 17442	4.9	0
332	The Delta SARS-CoV-2 variant has a higher viral load than the Beta and the historical variants in nasopharyngeal samples from newly diagnosed COVID-19 patients. <i>Journal of Infection</i> , 2021 , 83, e1-e3	18.9	63
331	SARS-CoV-2 infection in patients with primary central nervous system lymphoma. <i>Journal of Neurology</i> , 2021 , 268, 3072-3080	5.5	4
330	Kaposi's Sarcoma-Associated Herpesvirus, the Etiological Agent of All Epidemiological Forms of Kaposi's Sarcoma.. <i>Cancers</i> , 2021 , 13,	6.6	2
329	Neutrophil-Platelet and Monocyte-Platelet Aggregates in COVID-19 Patients. <i>Thrombosis and Haemostasis</i> , 2020 , 120, 1733-1735	7	15
328	Fatal Invasive Aspergillosis and Coronavirus Disease in an Immunocompetent Patient. <i>Emerging Infectious Diseases</i> , 2020 , 26, 1636-1637	10.2	85

327	Frequency of capsid substitutions associated with GS-6207 in vitro resistance in HIV-1 from antiretroviral-naïve and -experienced patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2020 , 75, 1588-1590	5.1	15
326	The First Locally Acquired Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection in a Healthcare Worker in the Paris Area. <i>Clinical Infectious Diseases</i> , 2020 , 71, e530-e531	11.6	6
325	M184V/I does not impact the efficacy of abacavir/lamivudine/dolutegravir use as switch therapy in virologically suppressed patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2020 , 75, 1290-1293	5.1	4
324	Characterization of drug resistance and the defective HIV reservoir in virally suppressed vertically infected children in Mali. <i>Journal of Antimicrobial Chemotherapy</i> , 2020 , 75, 1272-1279	5.1	0
323	Prevalence of doravirine-associated resistance mutations in HIV-1-infected antiretroviral-experienced patients from two large databases in France and Italy. <i>Journal of Antimicrobial Chemotherapy</i> , 2020 , 75, 1026-1030	5.1	12
322	Characterization of viral rebounds on dual etravirine/raltegravir maintenance therapy (ANRS-163 ETRAL trial). <i>Journal of Antimicrobial Chemotherapy</i> , 2020 , 75, 1943-1949	5.1	0
321	Discovery, SAR study and ADME properties of methyl 4-amino-3-cyano-1-(2-benzoyloxyphenyl)-1-pyrazole-5-carboxylate as an HIV-1 replication inhibitor. <i>RSC Medicinal Chemistry</i> , 2020 , 11, 577-582	3.5	3
320	New Kaposi's sarcoma-associated herpesvirus variant in men who have sex with men associated with severe pathologies. <i>Journal of Infectious Diseases</i> , 2020 , 222, 1320-1328	7	7
319	Methods comparison for molecular diagnosis of human herpesvirus 8 infections. <i>Journal of Clinical Virology</i> , 2020 , 126, 104308	14.5	1
318	Long-term follow-up of HIV-infected patients on dolutegravir monotherapy. <i>Journal of Antimicrobial Chemotherapy</i> , 2020 , 75, 675-680	5.1	1
317	Previously unreported emergence of A265V substitution in the integrase gene in association with bictegravir virological failure. <i>International Journal of Antimicrobial Agents</i> , 2020 , 56, 106039	14.3	1
316	Ultradeep sequencing reveals HIV-1 diversity and resistance compartmentalization during HIV-encephalopathy. <i>Aids</i> , 2020 , 34, 1609-1614	3.5	1
315	Multicenter comparison of the Cobas 6800 system with the RealStar RT-PCR kit for the detection of SARS-CoV-2. <i>Journal of Clinical Virology</i> , 2020 , 130, 104573	14.5	11
314	Dual therapy combining raltegravir with etravirine maintains a high level of viral suppression over 96 weeks in long-term experienced HIV-infected individuals over 45 years on a PI-based regimen: results from the Phase II ANRS 163 ETRAL study-authors' response. <i>Journal of Antimicrobial Chemotherapy</i> , 2020 , 75, 3699-3700	5.1	1
313	No HIV-1 molecular evolution on long-term antiretroviral therapy initiated during primary HIV-1 infection. <i>Aids</i> , 2020 , 34, 1745-1753	3.5	3
312	Integrase strand transfer inhibitor (INSTI)-resistance mutations for the surveillance of transmitted HIV-1 drug resistance. <i>Journal of Antimicrobial Chemotherapy</i> , 2020 , 75, 170-182	5.1	17
311	Recurrence and Occurrence of Kaposi's Sarcoma in Patients Living With Human Immunodeficiency Virus (HIV) and on Antiretroviral Therapy, Despite Suppressed HIV Viremia. <i>Clinical Infectious Diseases</i> , 2020 , 70, 2435-2438	11.6	11
310	Variability of the HIV-1 3' noncoding region (3'NCR) and implication in integrase inhibitor resistance. <i>Journal of Antimicrobial Chemotherapy</i> , 2019 , 74, 3440-3444	5.1	3

309	Evaluation of Two HIV Rapid Diagnostic Tests in a Context of Strains Genetic Diversity in Mali. <i>AIDS Research and Human Retroviruses</i> , 2019 , 35, 145-149	1.6	2
308	INSTI-Based Triple Regimens in Treatment-Naïve HIV-Infected Patients Are Associated With HIV-RNA Viral Load Suppression at Ultralow Levels. <i>Open Forum Infectious Diseases</i> , 2019 , 6, ofz177	1	2
307	Uncommon Detection of Mixed HCV Genotype Infections in Recently Infected Men Who Have Sex with Men. <i>International Journal of Antimicrobial Agents</i> , 2019 , 54, 513-517	14.3	
306	New mechanisms of resistance in virological failure to protease inhibitors: selection of non-described protease, Gag and Gp41 mutations. <i>Journal of Antimicrobial Chemotherapy</i> , 2019 , 74, 2019-2023	5.1	6
305	Lack of a Clinically Significant Pharmacokinetic Interaction between Etravirine and Raltegravir Using an Original Approach Based on Drug Metabolism, Protein Binding, and Penetration in Seminal Fluid: A Pharmacokinetic Substudy of the ANRS-163 ETRAL Study. <i>Pharmacotherapy</i> , 2019 , 39, 514-520	5.8	2
304	Resistance to integrase inhibitors: a national study in HIV-1-infected treatment-naïve and -experienced patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2019 , 74, 1368-1375	5.1	6
303	High clustering of acute HCV infections and high rate of associated STIs among Parisian HIV-positive male patients. <i>International Journal of Antimicrobial Agents</i> , 2019 , 53, 678-681	14.3	2
302	New resistance mutations to nucleoside reverse transcriptase inhibitors at codon 184 of HIV-1 reverse transcriptase (M184L and M184T). <i>Chemical Biology and Drug Design</i> , 2019 , 93, 50-59	2.9	2
301	Antiretroviral drug reduction in highly experienced HIV-infected patients receiving a multidrug regimen: the ECOVIR study. <i>Journal of Antimicrobial Chemotherapy</i> , 2019 , 74, 2716-2722	5.1	1
300	Dual therapy combining raltegravir with etravirine maintains a high level of viral suppression over 96 weeks in long-term experienced HIV-infected individuals over 45 years on a PI-based regimen: results from the Phase II ANRS 163 ETRAL study. <i>Journal of Antimicrobial Chemotherapy</i> , 2019 , 74, 2742-2751	5.1	17
299	New HIV-1 circulating recombinant form 94: from phylogenetic detection of a large transmission cluster to prevention in the age of geosocial-networking apps in France, 2013 to 2017. <i>Eurosurveillance</i> , 2019 , 24,	19.8	3
298	HIV-1 protease, Gag and gp41 baseline substitutions associated with virological response to a PI-based regimen. <i>Journal of Antimicrobial Chemotherapy</i> , 2019 , 74, 1679-1692	5.1	6
297	Seroprevalence and risk factors for HIV, HCV, HBV and syphilis among blood donors in Mali. <i>BMC Infectious Diseases</i> , 2019 , 19, 1064	4	10
296	Caution is needed in interpreting HIV transmission chains by ultradeep sequencing. <i>Aids</i> , 2019 , 33, 691-699	3.3	6
295	Human Immunodeficiency Virus (HIV)-Antibody Repertoire Estimates Reservoir Size and Time of Antiretroviral Therapy Initiation in Virally Suppressed Perinatally HIV-Infected Children. <i>Journal of the Pediatric Infectious Diseases Society</i> , 2019 , 8, 433-438	4.8	21
294	Rare occurrence of doravirine resistance-associated mutations in HIV-1-infected treatment-naïve patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2019 , 74, 614-617	5.1	16
293	Predicted antiviral activity of tenofovir versus abacavir in combination with a cytosine analogue and the integrase inhibitor dolutegravir in HIV-1-infected South African patients initiating or failing first-line ART. <i>Journal of Antimicrobial Chemotherapy</i> , 2019 , 74, 473-479	5.1	10
292	Impact of Next-generation Sequencing Defined Human Immunodeficiency Virus Pretreatment Drug Resistance on Virological Outcomes in the ANRS 12249 Treatment-as-Prevention Trial. <i>Clinical Infectious Diseases</i> , 2019 , 69, 207-214	11.6	38

291	Net emergence of substitutions at position 28 in NS5A of hepatitis C virus genotype 4 in patients failing direct-acting antivirals detected by next-generation sequencing. <i>International Journal of Antimicrobial Agents</i> , 2019 , 53, 80-83	14.3	6
290	Chronic hepatitis E in a heart transplant patient: sofosbuvir and ribavirin regimen not fully effective. <i>Antiviral Therapy</i> , 2018 , 23, 463-465	1.6	20
289	Dolutegravir resistance mutations: lessons from monotherapy studies. <i>Current Opinion in Infectious Diseases</i> , 2018 , 31, 237-245	5.4	23
288	Usefulness of Kaposi's Sarcoma-Associated Herpesvirus (KSHV) DNA Viral Load in Whole Blood for Diagnosis and Monitoring of KSHV-Associated Diseases. <i>Journal of Clinical Microbiology</i> , 2018 , 56,	9.7	7
287	Pathway involving the N155H mutation in HIV-1 integrase leads to dolutegravir resistance. <i>Journal of Antimicrobial Chemotherapy</i> , 2018 , 73, 1158-1166	5.1	8
286	Phenotypic analysis of HIV-1 E157Q integrase polymorphism and impact on virological outcome in patients initiating an integrase inhibitor-based regimen. <i>Journal of Antimicrobial Chemotherapy</i> , 2018 , 73, 1039-1044	5.1	29
285	Universal test and treat and the HIV epidemic in rural South Africa: a phase 4, open-label, community cluster randomised trial. <i>Lancet HIV</i> , 2018 , 5, e116-e125	7.8	140
284	Bridging Cyclodextrin Prevents Self-Inclusion, Promotes Supramolecular Polymerization, and Promotes Cooperative Interaction with Nucleic Acids. <i>Angewandte Chemie - International Edition</i> , 2018 , 57, 7753-7758	16.4	25
283	Emerging resistance mutations in PI-naïve patients failing an atazanavir-based regimen (ANRS multicentre observational study). <i>Journal of Antimicrobial Chemotherapy</i> , 2018 , 73, 2147-2151	5.1	1
282	Cost-effectiveness of dolutegravir/abacavir/lamivudine in HIV-1 treatment-Naïve (TN) patients in France. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2018 , 18, 83-91	2.2	5
281	No impact of HIV-1 protease minority resistant variants on the virological response to a first-line PI-based regimen containing darunavir or atazanavir. <i>Journal of Antimicrobial Chemotherapy</i> , 2018 , 73, 173-176	5.1	11
280	Resistance profile and treatment outcomes in HIV-infected children at virological failure in Benin, West Africa. <i>Journal of Antimicrobial Chemotherapy</i> , 2018 , 73, 3143-3147	5.1	8
279	Prevalence and clinical impact of minority resistant variants in patients failing an integrase inhibitor-based regimen by ultra-deep sequencing. <i>Journal of Antimicrobial Chemotherapy</i> , 2018 , 73, 2485-2492	5.1	13
278	Impact of Human Immunodeficiency Virus Type 1 Minority Variants on the Virus Response to a Rilpivirine-Based First-line Regimen. <i>Clinical Infectious Diseases</i> , 2018 , 66, 1588-1594	11.6	11
277	Characterization update of HIV-1 M subtypes diversity and proposal for subtypes A and D sub-subtypes reclassification. <i>Retrovirology</i> , 2018 , 15, 80	3.6	13
276	Evaluation of different analysis pipelines for the detection of HIV-1 minority resistant variants. <i>PLoS ONE</i> , 2018 , 13, e0198334	3.7	8
275	Dynamics of drug resistance-associated mutations in HIV-1 DNA reverse transcriptase sequence during effective ART. <i>Journal of Antimicrobial Chemotherapy</i> , 2018 , 73, 2141-2146	5.1	8
274	Reply to Das and Berkhout, "How Polypurine Tract Changes in the HIV-1 RNA Genome Can Cause Resistance against the Integrase Inhibitor Dolutegravir". <i>MBio</i> , 2018 , 9,	7.8	8

273	Ultrasensitive Human Immunodeficiency Virus Type 1 Viral Load as a Marker of Treatment Choice for Simplification Strategies. <i>Clinical Infectious Diseases</i> , 2018 , 67, 1883-1889	11.6	2
272	State of the Art in HIV Drug Resistance: Science and Technology Knowledge Gap. <i>AIDS Reviews</i> , 2018 , 20, 27-42	1.5	7
271	Ultradeep sequencing detection of the R263K integrase inhibitor drug resistance mutation. <i>Journal of Antimicrobial Chemotherapy</i> , 2017 , 72, 1537-1539	5.1	3
270	Quality of life improvement in HIV-1 patients treated with raltegravir in a real-life observational study: RACING. <i>HIV Clinical Trials</i> , 2017 , 18, 1-16		7
269	iNKT and memory B-cell alterations in HHV-8 multicentric Castleman disease. <i>Blood</i> , 2017 , 129, 855-865	2.2	10
268	High Rates of Baseline Drug Resistance and Virologic Failure Among ART-naïve HIV-infected Children in Mali. <i>Pediatric Infectious Disease Journal</i> , 2017 , 36, e258-e263	3.4	18
267	Antiretroviral-treated HIV-1 patients can harbour resistant viruses in CSF despite an undetectable viral load in plasma. <i>Journal of Antimicrobial Chemotherapy</i> , 2017 , 72, 2351-2354	5.1	6
266	Transient HIV-specific T cells increase and inflammation in an HIV-infected patient treated with nivolumab. <i>Aids</i> , 2017 , 31, 1048-1051	3.5	61
265	HIV-1 diagnosis with unquantifiable viraemia: don't be naïve, look for antiretroviral drugs. <i>Journal of Antimicrobial Chemotherapy</i> , 2017 , 72, 630-632	5.1	0
264	Mutations Located outside the Integrase Gene Can Confer Resistance to HIV-1 Integrase Strand Transfer Inhibitors. <i>MBio</i> , 2017 , 8,	7.8	39
263	Multicenter comparison of the new Cobas 6800 system with Cobas Ampliprep/Cobas TaqMan and Abbott RealTime for the quantification of HIV, HBV and HCV viral load. <i>Journal of Clinical Virology</i> , 2017 , 96, 49-53	14.5	22
262	De Novo Human Herpesvirus 8 Tumors Induced by Rituximab in Autoimmune or Inflammatory Systemic Diseases. <i>Arthritis and Rheumatology</i> , 2017 , 69, 2241-2246	9.5	6
261	Characterization of a <i>Propionibacterium acnes</i> Surface Protein as a Fibrinogen-Binding Protein. <i>Scientific Reports</i> , 2017 , 7, 6428	4.9	14
260	Addition of Etravirine Does Not Enhance the Initial Decline of HIV-1 RNA in Treatment-Experienced Patients Receiving Raltegravir. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2017 , 75, 448-454	3.1	1
259	Phase II Trial of Lenalidomide in HIV-Infected Patients with Previously Treated Kaposi's Sarcoma: Results of the ANRS 154 Lenakap Trial. <i>AIDS Research and Human Retroviruses</i> , 2017 , 33, 1-10	1.6	20
258	Risk of HIV transmission during combined ART initiation for HIV-infected persons with severe immunosuppression. <i>Journal of Antimicrobial Chemotherapy</i> , 2017 , 72, 3172-3176	5.1	4
257	Qualitative and quantitative HIV antibodies and viral reservoir size characterization in vertically infected children with virological suppression. <i>Journal of Antimicrobial Chemotherapy</i> , 2017 , 72, 1147-1151	5.1	9
256	Systematic review to determine the prevalence of transmitted drug resistance mutations to rilpivirine in HIV-infected treatment-naïve persons. <i>Antiviral Therapy</i> , 2016 , 21, 405-12	1.6	13

255	Treatment intensification followed by interleukin-7 reactivates HIV without reducing total HIV DNA: a randomized trial. <i>Aids</i> , 2016 , 30, 221-30	3.5	43
254	Usefulness of an HIV DNA resistance genotypic test in patients who are candidates for a switch to the rilpivirine/emtricitabine/tenofovir disoproxil fumarate combination. <i>Journal of Antimicrobial Chemotherapy</i> , 2016 , 71, 2248-51	5.1	10
253	Dolutegravir as monotherapy in HIV-1-infected individuals with suppressed HIV viraemia. <i>Journal of Antimicrobial Chemotherapy</i> , 2016 , 71, 2646-50	5.1	41
252	Host and disease factors are associated with cognitive function in European HIV-infected adults prior to initiation of antiretroviral therapy. <i>HIV Medicine</i> , 2016 , 17, 471-8	2.7	7
251	Determinants of a Low CD4/CD8 Ratio in HIV-1-Infected Individuals Despite Long-term Viral Suppression. <i>Clinical Infectious Diseases</i> , 2016 , 62, 1297-1303	11.6	44
250	Performance of genotypic algorithms for predicting tropism of HIV-1CRF02_AG subtype. <i>Journal of Clinical Virology</i> , 2016 , 76, 51-4	14.5	5
249	Antiretroviral resistance at virological failure in the NEAT 001/ANRS 143 trial: raltegravir plus darunavir/ritonavir or tenofovir/emtricitabine plus darunavir/ritonavir as first-line ART. <i>Journal of Antimicrobial Chemotherapy</i> , 2016 , 71, 1056-62	5.1	17
248	TLR-2 Recognizes Propionibacterium acnes CAMP Factor 1 from Highly Inflammatory Strains. <i>PLoS ONE</i> , 2016 , 11, e0167237	3.7	42
247	Expression pattern of the CXCL12/CXCR4-CXCR7 trio in Kaposi sarcoma skin lesions. <i>British Journal of Dermatology</i> , 2016 , 175, 1251-1262	4	10
246	Residual immune activation in combined antiretroviral therapy-treated patients with maximally suppressed viremia. <i>Aids</i> , 2016 , 30, 327-30	3.5	23
245	Presence of Minority Resistant Variants After Failure of a Tenofovir, Emtricitabine, and Rilpivirine Regimen. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2016 , 72, e43-5	3.1	2
244	Efficacy of protease inhibitor monotherapy vs. triple therapy: meta-analysis of data from 2303 patients in 13 randomized trials. <i>HIV Medicine</i> , 2016 , 17, 358-67	2.7	53
243	Efficacy and safety of once-daily ritonavir-boosted atazanavir or darunavir in combination with a dual nucleos(t)ide analogue backbone in HIV-1-infected combined ART (cART)-naïve patients with severe immunosuppression: a 48 week, non-comparative, randomized, multicentre trial (IMEA 040 DATA trial). <i>Journal of Antimicrobial Chemotherapy</i> , 2016 , 71, 2252-61	5.1	6
242	Factors associated with virological response to a switch regimen containing maraviroc for antiretroviral-experienced HIV-1-infected patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2016 , 71, 2651-3	5.1	5
241	Efficacy of etravirine combined with darunavir or other ritonavir-boosted protease inhibitors in HIV-1-infected patients: an observational study using pooled European cohort data. <i>HIV Medicine</i> , 2015 , 16, 297-306	2.7	8
240	Virological failure of patients on maraviroc-based antiretroviral therapy. <i>Journal of Antimicrobial Chemotherapy</i> , 2015 , 70, 1858-64	5.1	7
239	Improved detection of resistance at failure to a tenofovir, emtricitabine and efavirenz regimen by ultradeep sequencing. <i>Journal of Antimicrobial Chemotherapy</i> , 2015 , 70, 1503-6	5.1	16
238	Addressing social issues in a universal HIV test and treat intervention trial (ANRS 12249 TasP) in South Africa: methods for appraisal. <i>BMC Public Health</i> , 2015 , 15, 209	4.1	30

237	Low-level HIV-1 viraemia in patients on HAART: risk factors and management in clinical practice. <i>Journal of Antimicrobial Chemotherapy</i> , 2015 , 70, 2347-53	5.1	8
236	Virological factors associated with outcome of dual maraviroc/raltegravir therapy (ANRS-157 trial). <i>Journal of Antimicrobial Chemotherapy</i> , 2015 , 70, 3339-44	5.1	6
235	Combination of two pathways involved in raltegravir resistance confers dolutegravir resistance. <i>Journal of Antimicrobial Chemotherapy</i> , 2015 , 70, 2870-80	5.1	12
234	HIV-1 subtype B-infected MSM may have driven the spread of transmitted resistant strains in France in 2007-12: impact on susceptibility to first-line strategies. <i>Journal of Antimicrobial Chemotherapy</i> , 2015 , 70, 2084-9	5.1	39
233	Plasma concentrations of maraviroc and raltegravir after dual therapy in patients with long-term suppressed viraemia: ROCnRAL ANRS 157 study. <i>Journal of Antimicrobial Chemotherapy</i> , 2015 , 70, 2418-20	5.1	3
232	Incomplete APOBEC3G/F Neutralization by HIV-1 Vif Mutants Facilitates the Genetic Evolution from CCR5 to CXCR4 Usage. <i>Antimicrobial Agents and Chemotherapy</i> , 2015 , 59, 4870-81	5.9	8
231	Integrase inhibitor (INI) genotypic resistance in treatment-naïve and raltegravir-experienced patients infected with diverse HIV-1 clades. <i>Journal of Antimicrobial Chemotherapy</i> , 2015 , 70, 3080-6	5.1	56
230	Cost-Effectiveness of Dolutegravir/Abacavir/Lamivudine in Hiv-1 Treatment Naïve Patients in France. <i>Value in Health</i> , 2015 , 18, A587	3.3	2
229	Bone mineral density and inflammatory and bone biomarkers after darunavir-ritonavir combined with either raltegravir or tenofovir-emtricitabine in antiretroviral-naïve adults with HIV-1: a substudy of the NEAT001/ANRS143 randomised trial. <i>Lancet HIV</i> , 2015 , 2, e464-73	7.8	60
228	G118R and F121Y mutations identified in patients failing raltegravir treatment confer dolutegravir resistance. <i>Journal of Antimicrobial Chemotherapy</i> , 2015 , 70, 739-49	5.1	25
227	Antiretroviral-Experienced HIV-1-Infected Patients Treated with Maraviroc: Factors Associated with Virological Response. <i>AIDS Research and Human Retroviruses</i> , 2015 , 31, 475-8	1.6	2
226	Antiretroviral-naïve and -treated HIV-1 patients can harbour more resistant viruses in CSF than in plasma. <i>Journal of Antimicrobial Chemotherapy</i> , 2015 , 70, 566-72	5.1	7
225	Switch to maraviroc/raltegravir dual therapy leads to an unfavorable immune profile with low-level HIV viremia. <i>Aids</i> , 2015 , 29, 853-6	3.5	5
224	Soluble biomarkers of immune activation and inflammation in HIV infection: impact of 2 years of effective first-line combination antiretroviral therapy. <i>HIV Medicine</i> , 2015 , 16, 553-62	2.7	38
223	HIV-1 Coreceptor Usage Assessment by Ultra-Deep Pyrosequencing and Response to Maraviroc. <i>PLoS ONE</i> , 2015 , 10, e0127816	3.7	3
222	Cost-Effectiveness of Dolutegravir in HIV-1 Treatment-Experienced (TE) Patients in France. <i>PLoS ONE</i> , 2015 , 10, e0145885	3.7	5
221	Genetic barrier for attachment inhibitor BMS-626529 resistance in HIV-1 B and non-B subtypes. <i>Journal of Antimicrobial Chemotherapy</i> , 2015 , 70, 130-5	5.1	5
220	Very early ART resulting in the absence of HIV-1 antibodies and in a sustained undetectable plasma HIV-1-RNA and proviral-DNA in an HLA-B*5701 and B2 heterozygote HIV-1-infected patient was not associated with functional cure. <i>Journal of Antimicrobial Chemotherapy</i> , 2015 , 70, 317-9	5.1	1

219	Ultradeep sequencing in the therapeutic management of HIV-1 infection at treatment initiation. <i>Journal of Antimicrobial Chemotherapy</i> , 2015 , 70, 1919-20	5.1	
218	Cross-resistance to elvitegravir and dolutegravir in 502 patients failing on raltegravir: a French national study of raltegravir-experienced HIV-1-infected patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2015 , 70, 1507-12	5.1	43
217	HIV Replication Is Not Controlled by CD8+ T Cells during the Acute Phase of the Infection in Humanized Mice. <i>PLoS ONE</i> , 2015 , 10, e0138420	3.7	5
216	Efficacy of raltegravir switching strategies in HIV-infected patients with suppressed viraemia according to the genotypic sensitivity score. <i>Infection</i> , 2014 , 42, 295-301	5.8	1
215	Rilpivirine, emtricitabine and tenofovir resistance in HIV-1-infected rilpivirine-naïve patients failing antiretroviral therapy. <i>Journal of Antimicrobial Chemotherapy</i> , 2014 , 69, 1086-9	5.1	15
214	Factors associated with a low HIV reservoir in patients with prolonged suppressive antiretroviral therapy. <i>Journal of Antimicrobial Chemotherapy</i> , 2014 , 69, 753-6	5.1	40
213	New raltegravir resistance pathways induce broad cross-resistance to all currently used integrase inhibitors. <i>Journal of Antimicrobial Chemotherapy</i> , 2014 , 69, 2118-22	5.1	46
212	Comparative impact of antiretroviral drugs on markers of inflammation and immune activation during the first two years of effective therapy for HIV-1 infection: an observational study. <i>BMC Infectious Diseases</i> , 2014 , 14, 122	4	45
211	NRTI-sparing regimens yield higher rates of drug resistance than NRTI-based regimens for HIV-1 treatment. <i>Journal of Global Antimicrobial Resistance</i> , 2014 , 2, 103-106	3.4	1
210	The multifactorial pathways towards resistance to the cytosine analogues emtricitabine and lamivudine: evidences from literature. <i>Journal of Infection</i> , 2014 , 69, 408-10	18.9	2
209	Less frequent follow-up in routine care than in trials does not impact resistance selection in patients failing DRV/r or ATV/r first line treatment. <i>Journal of the International AIDS Society</i> , 2014 , 17, 19744	5.4	
208	Efficacy of PI monotherapy versus triple therapy for 1964 patients in 10 randomised trials. <i>Journal of the International AIDS Society</i> , 2014 , 17, 19788	5.4	16
207	Comparative replication capacity of raltegravir-resistant strains and antiviral activity of the new-generation integrase inhibitor dolutegravir in human primary macrophages and lymphocytes. <i>Journal of Antimicrobial Chemotherapy</i> , 2014 , 69, 2412-9	5.1	20
206	Rapid plasma viral suppression in naïve HIV-infected patients with high CD4 cells and low viraemia initiating a dual nucleoside reverse transcriptase inhibitor strategy: a proof-of-concept study. <i>Journal of Antimicrobial Chemotherapy</i> , 2014 , 69, 3356-9	5.1	1
205	Differential impact of APOBEC3-driven mutagenesis on HIV evolution in diverse anatomical compartments. <i>Aids</i> , 2014 , 28, 487-91	3.5	21
204	Maraviroc plus raltegravir failed to maintain virological suppression in HIV-infected patients with lipohypertrophy: results from the ROCnRAL ANRS 157 study. <i>Journal of Antimicrobial Chemotherapy</i> , 2014 , 69, 1648-52	5.1	26
203	High level of HIV-1 resistance in patients failing long-term first-line antiretroviral therapy in Mali. <i>Journal of Antimicrobial Chemotherapy</i> , 2014 , 69, 2531-5	5.1	18
202	A very low geno2pheno false positive rate is associated with poor viro-immunological response in drug-naïve patients starting a first-line HAART. <i>PLoS ONE</i> , 2014 , 9, e105853	3.7	9

201	Transmitted antiretroviral drug resistance in newly HIV-infected and untreated patients in Sgou and Bamako, Mali. <i>AIDS Research and Human Retroviruses</i> , 2013 , 29, 182-6	1.6	12
200	Switching to darunavir/ritonavir 800/100 mg once-daily containing regimen maintains virological control in fully suppressed pre-treated patients infected with HIV-1. <i>Journal of Medical Virology</i> , 2013 , 85, 8-15	19.7	11
199	Human herpesvirus 8 (HHV8) transmission and related morbidity in organ recipients. <i>American Journal of Transplantation</i> , 2013 , 13, 207-13	8.7	48
198	A cohort study of treatment-experienced HIV-1-infected patients treated with raltegravir: factors associated with virological response and mutations selected at failure. <i>International Journal of Antimicrobial Agents</i> , 2013 , 42, 42-7	14.3	19
197	Direct quantification of cell-associated HIV DNA in isolated rectal and blood memory CD4 T cells revealed their similar and low infection levels in long-term treated HIV-infected patients. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2013 , 62, 255-9	3.1	8
196	A single amino-acid change in a highly conserved motif of gp41 elicits HIV-1 neutralization and protects against CD4 depletion. <i>Clinical Infectious Diseases</i> , 2013 , 57, 745-55	11.6	11
195	Evolution of the K65R, K103N and M184V/I reverse transcriptase mutations in HIV-1-infected patients experiencing virological failure between 2005 and 2010. <i>Journal of Antimicrobial Chemotherapy</i> , 2013 , 68, 2197-8	5.1	13
194	HIV-1 integrase variability and relationship with drug resistance in antiretroviral-naïve and -experienced patients with different HIV-1 subtypes. <i>Journal of Antimicrobial Chemotherapy</i> , 2013 , 68, 969-72	5.1	7
193	Pitfalls of HIV genotypic tropism testing after treatment interruption. <i>Journal of Antimicrobial Chemotherapy</i> , 2013 , 68, 188-9	5.1	4
192	Genetic barrier to the development of resistance to rilpivirine and etravirine between HIV-1 subtypes CRF02_AG and B. <i>Journal of Antimicrobial Chemotherapy</i> , 2013 , 68, 2515-20	5.1	4
191	Pulmonary manifestations of human herpesvirus-8 during HIV infection. <i>European Respiratory Journal</i> , 2013 , 42, 1105-18	13.6	24
190	Prevalence of pre-existing resistance-associated mutations to rilpivirine, emtricitabine and tenofovir in antiretroviral-naïve patients infected with B and non-B subtype HIV-1 viruses. <i>Journal of Antimicrobial Chemotherapy</i> , 2013 , 68, 1237-42	5.1	38
189	HIV-1 dynamics and coreceptor usage in Maraviroc-treated patients with ongoing replication. <i>Antimicrobial Agents and Chemotherapy</i> , 2013 , 57, 930-5	5.9	16
188	Identification of a rare mutation at reverse transcriptase Lys65 (K65E) in HIV-1-infected patients failing on nucleos(t)ide reverse transcriptase inhibitors. <i>Journal of Antimicrobial Chemotherapy</i> , 2013 , 68, 2199-204	5.1	7
187	Highly multidrug-resistant HIV: clonal analysis and therapeutic strategies. <i>Journal of Antimicrobial Chemotherapy</i> , 2013 , 68, 2882-9	5.1	3
186	National sentinel surveillance of transmitted drug resistance in antiretroviral-naïve chronically HIV-infected patients in France over a decade: 2001-2011. <i>Journal of Antimicrobial Chemotherapy</i> , 2013 , 68, 2626-31	5.1	39
185	Prevalence of HIV-1 drug resistance in treated patients with viral load >50 copies/mL in 2009: a French nationwide study. <i>Journal of Antimicrobial Chemotherapy</i> , 2013 , 68, 1400-5	5.1	16
184	Frequency of amino acid changes associated with resistance to attachment inhibitor BMS-626529 in R5- and X4-tropic HIV-1 subtype B. <i>Journal of Antimicrobial Chemotherapy</i> , 2013 , 68, 1243-5	5.1	13

183	Description of the L76V resistance protease mutation in HIV-1 B and "non-B" subtypes. <i>PLoS ONE</i> , 2013 , 8, e54381	3.7	1
182	Scoring methods for building genotypic scores: an application to didanosine resistance in a large derivation set. <i>PLoS ONE</i> , 2013 , 8, e59014	3.7	2
181	A polymorphism at position 400 in the connection subdomain of HIV-1 reverse transcriptase affects sensitivity to NNRTIs and RNaseH activity. <i>PLoS ONE</i> , 2013 , 8, e74078	3.7	9
180	Human herpesvirus 8 transfusion transmission in Ghana, an endemic region of West Africa. <i>Transfusion</i> , 2012 , 52, 2294-9	2.9	7
179	Multicenter assessment of HIV-1 RNA quantitation in semen in the CREAThE network. <i>Journal of Medical Virology</i> , 2012 , 84, 183-7	19.7	8
178	The future of integrase inhibitors of HIV-1. <i>Current Opinion in Virology</i> , 2012 , 2, 580-7	7.5	20
177	HIV-1 genome is often defective in PBMCs and rectal tissues after long-term HAART as a result of APOBEC3 editing and correlates with the size of reservoirs. <i>Journal of Antimicrobial Chemotherapy</i> , 2012 , 67, 2323-6	5.1	41
176	Natural evolution of CD4+ cell count in patients with CD4 >350 or >500 cells/mm ³ at the time of diagnosis according to HIV-1 coreceptor tropism. <i>Journal of Medical Virology</i> , 2012 , 84, 1853-6	19.7	7
175	Impact of lopinavir/ritonavir use on antiretroviral resistance in recent clinical practice. <i>Journal of Antimicrobial Chemotherapy</i> , 2012 , 67, 2487-93	5.1	4
174	Emergence of cytomegalovirus resistance to foscarnet in a patient receiving foscarnet salvage therapy for multidrug-resistant HIV infection. <i>Journal of Clinical Virology</i> , 2012 , 54, 194-6	14.5	10
173	Similar evolution of cellular HIV-1 DNA level in darunavir/ritonavir monotherapy versus triple therapy in MONOI-ANRS136 trial over 96 weeks. <i>PLoS ONE</i> , 2012 , 7, e41390	3.7	23
172	In Silico and In Vitro Comparison of HIV-1 Subtypes B and CRF02_AG Integrases Susceptibility to Integrase Strand Transfer Inhibitors. <i>Advances in Virology</i> , 2012 , 2012, 548657	1.9	5
171	Risk factors for raltegravir resistance development in clinical practice. <i>Journal of Antimicrobial Chemotherapy</i> , 2012 , 67, 2494-500	5.1	9
170	E17A mutation in HIV-1 Vpr confers resistance to didanosine in association with thymidine analog mutations. <i>Antiviral Research</i> , 2012 , 93, 167-74	10.8	5
169	Emerging mutations and associated factors in patients displaying treatment failure on an etravirine-containing regimen. <i>Antiviral Therapy</i> , 2012 , 17, 119-23	1.6	6
168	Etravirine concentrations in the cervicovaginal compartment in HIV-1-infected women receiving etravirine-containing antiretroviral therapy: DIVA 02 study. <i>Antimicrobial Agents and Chemotherapy</i> , 2012 , 56, 4018-20	5.9	10
167	Characterization of HIV-1 antiretroviral drug resistance after second-line treatment failure in Mali, a limited-resources setting. <i>Journal of Antimicrobial Chemotherapy</i> , 2012 , 67, 2943-8	5.1	28
166	Investigation of Super Learner Methodology on HIV-1 Small Sample: Application on Jaguar Trial Data. <i>AIDS Research and Treatment</i> , 2012 , 2012, 478467	2.3	5

165	Resistant minority species are rarely observed in patients on darunavir/ritonavir monotherapy. <i>Journal of Antimicrobial Chemotherapy</i> , 2012 , 67, 1470-4	5.1	16
164	Coreceptor usage in different reservoirs. <i>Current Opinion in HIV and AIDS</i> , 2012 , 7, 450-5	4.2	5
163	Long-term efficacy of darunavir/ritonavir monotherapy in patients with HIV-1 viral suppression: week 96 results from the MONOI ANRS 136 study. <i>Journal of Antimicrobial Chemotherapy</i> , 2012 , 67, 691-5	5.1	51
162	Resistance profiles of emtricitabine and lamivudine in tenofovir-containing regimens. <i>Journal of Antimicrobial Chemotherapy</i> , 2012 , 67, 1475-8	5.1	23
161	Switch from etravirine twice daily to once daily in non-nucleoside reverse transcriptase inhibitor (NNRTI)-resistant HIV-infected patients with suppressed viremia: the Monetra study. <i>HIV Clinical Trials</i> , 2012 , 13, 284-8		7
160	Detection of HIV-1 RNA in seminal plasma samples from treated patients with undetectable HIV-1 RNA in blood plasma on a 2002-2011 survey. <i>Aids</i> , 2012 , 26, 971-5	3.5	63
159	Circulating interleukin-6 levels correlate with residual HIV viraemia and markers of immune dysfunction in treatment-controlled HIV-infected patients. <i>Antiviral Therapy</i> , 2012 , 17, 915-9	1.6	66
158	Connection domain mutations during antiretroviral treatment failure in Mali: frequencies and impact on reverse transcriptase inhibitor activity. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2012 , 61, 293-6	3.1	3
157	E138K and M184I mutations in HIV-1 reverse transcriptase coemerge as a result of APOBEC3 editing in the absence of drug exposure. <i>Aids</i> , 2012 , 26, 1619-24	3.5	33
156	Prevalence of resistance mutations related to integrase inhibitor S/GSK1349572 in HIV-1 subtype B raltegravir-naïve and -treated patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2011 , 66, 1481-3	5.1	17
155	Higher efficacy of nevirapine than efavirenz to achieve HIV-1 plasma viral load below 1 copy/mL. <i>Aids</i> , 2011 , 25, 341-4	3.5	38
154	Comprehensive analysis of virus-specific T-cells provides clues for the failure of therapeutic immunization with ALVAC-HIV vaccine. <i>Aids</i> , 2011 , 25, 27-36	3.5	37
153	High prevalence of antiretroviral drug resistance among HIV-1-untreated patients in Guinea-Conakry and in Niger. <i>Antiviral Therapy</i> , 2011 , 16, 429-33	1.6	21
152	Effect of antiretroviral drugs on the quality of semen. <i>Journal of Medical Virology</i> , 2011 , 83, 1391-4	19.7	22
151	Docking analysis and resistance evaluation of clinically relevant mutations associated with the HIV-1 non-nucleoside reverse transcriptase inhibitors nevirapine, efavirenz and etravirine. <i>ChemMedChem</i> , 2011 , 6, 2203-13	3.7	12
150	Upgraded Cobas Ampliprep-Cobas TaqMan version 2.0 HIV-1 RNA quantification assay versus first version: correction of underestimations. <i>Journal of Clinical Microbiology</i> , 2011 , 49, 2700-2	9.7	10
149	Improved V3 genotyping with duplicate PCR amplification for determining HIV-1 tropism. <i>Journal of Antimicrobial Chemotherapy</i> , 2011 , 66, 1972-5	5.1	12
148	Factors associated with virological failure in HIV-1-infected patients receiving darunavir/ritonavir monotherapy. <i>Journal of Infectious Diseases</i> , 2011 , 204, 1211-6	7	73

147	Concordance between two phenotypic assays and ultradeep pyrosequencing for determining HIV-1 tropism. <i>Antimicrobial Agents and Chemotherapy</i> , 2011 , 55, 2831-6	5.9	40
146	Raltegravir concentrations in the genital tract of HIV-1-infected women treated with a raltegravir-containing regimen (DIVA 01 study). <i>Antimicrobial Agents and Chemotherapy</i> , 2011 , 55, 3018-21	5.9	29
145	The HIV-1 integrase G118R mutation confers raltegravir resistance to the CRF02_AG HIV-1 subtype. <i>Journal of Antimicrobial Chemotherapy</i> , 2011 , 66, 2827-30	5.1	37
144	Impact of adding enfuvirtide to the predictive value of the darunavir genotypic resistance score. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2011 , 57, e15-7	3.1	
143	Low frequency of HIV-1 tropism evolution in patients successfully treated for at least 2 years. <i>Aids</i> , 2011 , 25, 537-9	3.5	11
142	Positive impact of HIV-1 gag cleavage site mutations on the virological response to darunavir boosted with ritonavir. <i>Antimicrobial Agents and Chemotherapy</i> , 2011 , 55, 1754-7	5.9	10
141	Historical HIV-RNA resistance test results are more informative than proviral DNA genotyping in cases of suppressed or residual viraemia. <i>Journal of Antimicrobial Chemotherapy</i> , 2011 , 66, 709-12	5.1	53
140	Impact of Y143 HIV-1 integrase mutations on resistance to raltegravir in vitro and in vivo. <i>Antimicrobial Agents and Chemotherapy</i> , 2010 , 54, 491-501	5.9	70
139	Increasing prevalence of transmitted drug resistance mutations and non-B subtype circulation in antiretroviral-naïve chronically HIV-infected patients from 2001 to 2006/2007 in France. <i>Journal of Antimicrobial Chemotherapy</i> , 2010 , 65, 2620-7	5.1	59
138	Level of viral load and antiretroviral resistance after 6 months of non-nucleoside reverse transcriptase inhibitor first-line treatment in HIV-1-infected children in Mali. <i>Journal of Antimicrobial Chemotherapy</i> , 2010 , 65, 118-24	5.1	46
137	Factors associated with virological response to etravirine in nonnucleoside reverse transcriptase inhibitor-experienced HIV-1-infected patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2010 , 54, 72-7	5.9	32
136	Factors associated with proviral DNA HIV-1 tropism in antiretroviral therapy-treated patients with fully suppressed plasma HIV viral load: implications for the clinical use of CCR5 antagonists. <i>Journal of Antimicrobial Chemotherapy</i> , 2010 , 65, 749-51	5.1	35
135	Discordance between cerebral spinal fluid and plasma HIV replication in patients with neurological symptoms who are receiving suppressive antiretroviral therapy. <i>Clinical Infectious Diseases</i> , 2010 , 50, 773-8	11.6	307
134	International cohort analysis of the antiviral activities of zidovudine and tenofovir in the presence of the K65R mutation in reverse transcriptase. <i>Antimicrobial Agents and Chemotherapy</i> , 2010 , 54, 1520-5	5.9	8
133	Evaluation of the genotypic prediction of HIV-1 coreceptor use versus a phenotypic assay and correlation with the virological response to maraviroc: the ANRS GenoTropism study. <i>Antimicrobial Agents and Chemotherapy</i> , 2010 , 54, 3335-40	5.9	61
132	Low frequency of intermittent HIV-1 semen excretion in patients treated with darunavir-ritonavir at 600/100 milligrams twice a day plus two nucleoside reverse transcriptase inhibitors or monotherapy. <i>Antimicrobial Agents and Chemotherapy</i> , 2010 , 54, 4910-3	5.9	22
131	Resistance-associated mutations to etravirine (TMC-125) in antiretroviral-naïve patients infected with non-B HIV-1 subtypes. <i>Antimicrobial Agents and Chemotherapy</i> , 2010 , 54, 728-33	5.9	42
130	Tetherin restricts productive HIV-1 cell-to-cell transmission. <i>PLoS Pathogens</i> , 2010 , 6, e1000955	7.6	127

129	Maraviroc does not affect humoral response to the pandemic influenza A-H1N1v 2009 adjuvanted vaccine in HIV-1-infected patients. <i>Aids</i> , 2010 , 24, 2887-9	3.5	9
128	Resistance to HIV-1 integrase inhibitors: A structural perspective. <i>Drug Resistance Updates</i> , 2010 , 13, 139-50	23.2	64
127	HIV-1 or hepatitis C chronic infection in serodiscordant infertile couples has no impact on infertility treatment outcome. <i>Fertility and Sterility</i> , 2010 , 93, 1020-3	4.8	25
126	Specific HIV-1 integrase polymorphisms change their prevalence in untreated versus antiretroviral-treated HIV-1-infected patients, all naive to integrase inhibitors. <i>Journal of Antimicrobial Chemotherapy</i> , 2010 , 65, 2305-18	5.1	53
125	Raltegravir as functional monotherapy leads to virological failure and drug resistance in highly treatment-experienced HIV-infected patients. <i>Scandinavian Journal of Infectious Diseases</i> , 2010 , 42, 527-32		13
124	Immune and virological benefits of 10 years of permanent viral control with antiretroviral therapy. <i>Aids</i> , 2010 , 24, 614-7	3.5	40
123	Patient-selected treatment partners did not protect against drug resistance during first-line NNRTI-based HAART in a randomized trial. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2010 , 54, 563-5	3.1	3
122	Efficacy of darunavir/ritonavir maintenance monotherapy in patients with HIV-1 viral suppression: a randomized open-label, noninferiority trial, MONOI-ANRS 136. <i>Aids</i> , 2010 , 24, 2365-74	3.5	133
121	Pharmacokinetics, protein-binding-adjusted inhibitory quotients for atazanavir/ritonavir 300/100 mg in treatment-naïve HIV-infected patients. <i>HIV Medicine</i> , 2010 , 11, 666-9	2.7	5
120	Partially active HIV-1 Vif alleles facilitate viral escape from specific antiretrovirals. <i>Aids</i> , 2010 , 24, 2313-23	3.5	51
119	HIV genetic diversity between plasma and cerebrospinal fluid in patients with HIV encephalitis. <i>Aids</i> , 2010 , 24, 2412-4	3.5	26
118	Quasispecies variant dynamics during emergence of resistance to raltegravir in HIV-1-infected patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2009 , 63, 795-804	5.1	82
117	Raltegravir has no residual antiviral activity in vivo against HIV-1 with resistance-associated mutations to this drug. <i>Journal of Antimicrobial Chemotherapy</i> , 2009 , 64, 1087-90	5.1	23
116	Antiretroviral combinations implicated in emergence of the L74I and L74V resistance mutations in HIV-1-infected patients. <i>Aids</i> , 2009 , 23, 95-9	3.5	13
115	Nucleoside reverse transcriptase inhibitor-sparing regimen (nonnucleoside reverse transcriptase inhibitor + protease inhibitor) was more likely associated with resistance comparing to nonnucleoside reverse transcriptase inhibitor or protease inhibitor + nucleoside reverse transcriptase inhibitor in the randomized ANRS 121 trial. <i>Aids</i> , 2009 , 23, 1605-8	3.5	10
114	Mutations associated with virological response to darunavir/ritonavir in HIV-1-infected protease inhibitor-experienced patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2009 , 63, 585-92	5.1	33
113	Impact of discrepancies between the Abbott realtime and cobas TaqMan assays for quantification of human immunodeficiency virus type 1 group M non-B subtypes. <i>Journal of Clinical Microbiology</i> , 2009 , 47, 1543-5	9.7	29
112	The impact of preexisting or acquired Kaposi sarcoma herpesvirus infection in kidney transplant recipients on morbidity and survival. <i>American Journal of Transplantation</i> , 2009 , 9, 2580-6	8.7	53

111	HIV-1 IN alternative molecular recognition of DNA induced by raltegravir resistance mutations. <i>Journal of Molecular Recognition</i> , 2009 , 22, 480-94	2.6	13
110	Identification of new genotypic cut-off levels to predict the efficacy of lopinavir/ritonavir and darunavir/ritonavir in the TITAN trial. <i>HIV Medicine</i> , 2009 , 10, 620-6	2.7	4
109	Resistance to novel drug classes. <i>Current Opinion in HIV and AIDS</i> , 2009 , 4, 531-7	4.2	20
108	Presence of HIV-1 R5 viruses in cerebrospinal fluid even in patients harboring R5X4/X4 viruses in plasma. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2009 , 51, 60-4	3.1	35
107	Effect of lentivirus encoding HIV-1 Nef-U3 shRNA on the function of HIV-specific memory CD4(+) T cells in patients with chronic HIV-1 infection. <i>Aids</i> , 2009 , 23, 2265-75	3.5	3
106	The G140S mutation in HIV integrases from raltegravir-resistant patients rescues catalytic defect due to the resistance Q148H mutation. <i>Nucleic Acids Research</i> , 2009 , 37, 1193-201	20.1	115
105	Characterization and structural analysis of HIV-1 integrase conservation. <i>AIDS Reviews</i> , 2009 , 11, 17-29	1.5	112
104	Genetic barriers for integrase inhibitor drug resistance in HIV type-1 B and CRF02_AG subtypes. <i>Antiviral Therapy</i> , 2009 , 14, 123-9	1.6	19
103	Genetic barriers for integrase inhibitor drug resistance in HIV type-1 B and CRF02_AG subtypes. <i>Antiviral Therapy</i> , 2009 , 14, 123-129	1.6	33
102	Comparison of two genotypic algorithms to determine HIV-1 tropism. <i>HIV Medicine</i> , 2008 , 9, 1-5	2.7	17
101	Stability of HIV RNA in plasma specimens stored at different temperatures. <i>HIV Medicine</i> , 2008 , 9, 790-3	2.7	10
100	Detection of human herpesviruses HHV-6, HHV-7 and HHV-8 in whole blood by real-time PCR using the new CMV, HHV-6, 7, 8 R-gene kit. <i>Journal of Virological Methods</i> , 2008 , 149, 285-91	2.6	20
99	Impact of gag mutations on selection of darunavir resistance mutations in HIV-1 protease. <i>Journal of Antimicrobial Chemotherapy</i> , 2008 , 62, 905-8	5.1	16
98	Factors associated with the selection of mutations conferring resistance to protease inhibitors (PIs) in PI-experienced patients displaying treatment failure on darunavir. <i>Antimicrobial Agents and Chemotherapy</i> , 2008 , 52, 491-6	5.9	38
97	Primary genotypic resistance of HIV-1 to CCR5 antagonists in CCR5 antagonist treatment-naïve patients. <i>Aids</i> , 2008 , 22, 2212-4	3.5	21
96	Kaposi's sarcoma in HIV-negative men having sex with men. <i>Aids</i> , 2008 , 22, 1163-8	3.5	44
95	Detection of HIV-1 RNA in seminal plasma samples from treated patients with undetectable HIV-1 RNA in blood plasma. <i>Aids</i> , 2008 , 22, 1677-9	3.5	77
94	Predictive Genotypic Algorithm for Virologic Response to Lopinavir-Ritonavir in Protease Inhibitor-Experienced Patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2008 , 52, 811-811	5.9	78

93	Tipranavir-ritonavir genotypic resistance score in protease inhibitor-experienced patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2008 , 52, 3237-43	5.9	40
92	HIV-1-infected patients from the French National Observatory experiencing virological failure while receiving enfuvirtide. <i>Journal of Antimicrobial Chemotherapy</i> , 2008 , 62, 451-5	5.1	5
91	Genotypic resistance analysis of the virological response to fosamprenavir-ritonavir in protease inhibitor-experienced patients in CONTEXT and TRIAD clinical trials. <i>Antimicrobial Agents and Chemotherapy</i> , 2008 , 52, 4251-7	5.9	8
90	Antiretroviral therapy with a twice-daily regimen containing 400 milligrams of indinavir and 100 milligrams of ritonavir in human immunodeficiency virus type 1-infected women during pregnancy. <i>Antimicrobial Agents and Chemotherapy</i> , 2008 , 52, 1542-4	5.9	13
89	Clinically validated mutation scores for HIV-1 resistance to fosamprenavir/ritonavir. <i>Journal of Antimicrobial Chemotherapy</i> , 2008 , 61, 1362-8	5.1	11
88	Evolution of genetic diversity and drug resistance mutations in HIV-1 among untreated patients from Mali between 2005 and 2006. <i>Journal of Antimicrobial Chemotherapy</i> , 2008 , 62, 456-63	5.1	28
87	The involvement of HIV-1 RNase H in resistance to nucleoside analogues. <i>Journal of Antimicrobial Chemotherapy</i> , 2008 , 61, 973-5	5.1	12
86	Mutations associated with failure of raltegravir treatment affect integrase sensitivity to the inhibitor in vitro. <i>Antimicrobial Agents and Chemotherapy</i> , 2008 , 52, 1351-8	5.9	235
85	Multicentric Castleman disease is associated with polyfunctional effector memory HHV-8-specific CD8+ T cells. <i>Blood</i> , 2008 , 111, 1387-95	2.2	38
84	The marriage of science and optimized HIV care in resource-limited settings. <i>Aids</i> , 2008 , 22, 2227-30	3.5	4
83	National survey of the prevalence and conditions of selection of HIV-1 reverse transcriptase K70E mutation. <i>Journal of Medical Virology</i> , 2008 , 80, 762-5	19.7	6
82	Structural effects of amino acid variations between B and CRF02_AG HIV-1 integrases. <i>Journal of Medical Virology</i> , 2008 , 80, 754-61	19.7	20
81	Relationship between mutations in HIV-1 RNase H domain and nucleoside reverse transcriptase inhibitors resistance mutations in naïve and pre-treated HIV infected patients. <i>Journal of Medical Virology</i> , 2007 , 79, 207-11	19.7	21
80	Association of Gag cleavage sites to protease mutations and to virological response in HIV-1 treated patients. <i>Journal of Infection</i> , 2007 , 54, 367-74	18.9	46
79	Transmission of multidrug-resistant HIV-1: 5 years of immunological and virological survey. <i>Aids</i> , 2007 , 21, 1365-7	3.5	7
78	Experience of indinavir/ritonavir 400/100 mg twice-daily highly active antiretroviral therapy-containing regimen in HIV-1-infected patients in Bamako, Mali: the NOGOMA Study. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2007 , 45, 477-9	3.1	4
77	Primary genotypic resistance of HIV-1 to the maturation inhibitor PA-457 in protease inhibitor-experienced patients. <i>Aids</i> , 2007 , 21, 871-3	3.5	16
76	Superior control of HIV-1 replication by CD8+ T cells is reflected by their avidity, polyfunctionality, and clonal turnover. <i>Journal of Experimental Medicine</i> , 2007 , 204, 2473-85	16.6	560

75	Relationship between the quantity of Kaposi sarcoma-associated herpesvirus (KSHV) in peripheral blood and effusion fluid samples and KSHV-associated disease. <i>Journal of Infectious Diseases</i> , 2007 , 196, 1163-6	7	54
74	Predictive genotypic algorithm for virologic response to lopinavir-ritonavir in protease inhibitor-experienced patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2007 , 51, 3067-74	5.9	27
73	Phenotypic susceptibility to didanosine is associated with antiviral activity in treatment-experienced patients with HIV-1 infection. <i>Journal of Infectious Diseases</i> , 2007 , 195, 392-8	7	14
72	The first reported case and management of multicentric Castleman's disease associated with Kaposi's sarcoma in an HIV-2-infected patient. <i>Aids</i> , 2007 , 21, 1492-4	3.5	6
71	HIV drug resistance after the use of generic fixed-dose combination stavudine/lamivudine/nevirapine as standard first-line regimen. <i>Aids</i> , 2007 , 21, 2341-3	3.5	22
70	HIV-1 X4/R5 co-receptor in viral reservoir during suppressive HAART. <i>Aids</i> , 2007 , 21, 2243-5	3.5	27
69	Prevalence of HIV-1 drug resistance in treated patients: a French nationwide study. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2007 , 46, 12-8	3.1	47
68	Clinical validation of saquinavir/ritonavir genotypic resistance score in protease-inhibitor-experienced patients. <i>Antiviral Therapy</i> , 2007 , 12, 247-52	1.6	6
67	Genetic diversity and drug resistance mutations in HIV type 1 from untreated patients in Bamako, Mali. <i>Antiviral Therapy</i> , 2007 , 12, 123-9	1.6	14
66	Clinical Validation of Saquinavir/Ritonavir Genotypic Resistance Score in Protease-Inhibitor-Experienced Patients. <i>Antiviral Therapy</i> , 2007 , 12, 247-252	1.6	6
65	Repeated HIV-1 resistance genotyping external quality assessments improve virology laboratory performance. <i>Journal of Medical Virology</i> , 2006 , 78, 153-60	19.7	53
64	Multicenter quality control of the detection of HIV-1 genome in semen before medically assisted procreation. <i>Journal of Medical Virology</i> , 2006 , 78, 877-82	19.7	37
63	Risk factors for selection of the L74I reverse transcriptase mutation in human immunodeficiency virus type 1-infected patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2006 , 50, 2553-6	5.9	6
62	Low T cell responses to human herpesvirus 8 in patients with AIDS-related and classic Kaposi sarcoma. <i>Journal of Infectious Diseases</i> , 2006 , 194, 1078-88	7	98
61	Safety and efficacy of adefovir dipivoxil in patients infected with lamivudine-resistant hepatitis B and HIV-1. <i>Journal of Hepatology</i> , 2006 , 44, 62-7	13.4	74
60	Clinical validation of atazanavir/ritonavir genotypic resistance score in protease inhibitor-experienced patients. <i>Aids</i> , 2006 , 20, 35-40	3.5	45
59	Role of HIV-1 minority populations on resistance mutational pattern evolution and susceptibility to protease inhibitors. <i>Aids</i> , 2006 , 20, 287-9	3.5	24
58	External validation of atazanavir/ritonavir genotypic score in HIV-1 protease inhibitor-experienced patients. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2006 , 42, 127-8	3.1	5

57	Impact of HIV-1 reverse transcriptase polymorphism at codons 211 and 228 on virological response to didanosine. <i>Antiviral Therapy</i> , 2006 , 11, 693-9	1.6	4
56	Impact of HIV-1 Reverse Transcriptase Polymorphism at Codons 211 and 228 on Virological Response to Didanosine. <i>Antiviral Therapy</i> , 2006 , 11, 693-700	1.6	6
55	Salvage Therapy with Atazanavir/Ritonavir Combined to Tenofovir in HIV-Infected Patients with Multiple Treatment Failures: Randomized Anrs 107 Trial. <i>Antiviral Therapy</i> , 2006 , 11, 213-222	1.6	5
54	HIV-1 intermittent viraemia in patients treated by non-nucleoside reverse transcriptase inhibitor-based regimen. <i>Aids</i> , 2005 , 19, 1065-9	3.5	26
53	Persistent low viral load on antiretroviral therapy is associated with T cell-mediated control of HIV replication. <i>Aids</i> , 2005 , 19, 25-33	3.5	43
52	Efficacy of interferon-alpha for the treatment of Kaposi's sarcoma herpesvirus-associated uveitis. <i>American Journal of Ophthalmology</i> , 2005 , 140, 746-8	4.9	14
51	Clonal analyses of HIV quasispecies in patients harbouring plasma genotype with K65R mutation associated with thymidine analogue mutations or L74V substitution. <i>Aids</i> , 2005 , 19, 630-2	3.5	17
50	Human herpes virus 8 in HIV and non-HIV infected patients with pulmonary arterial hypertension in France. <i>Aids</i> , 2005 , 19, 1239-40	3.5	25
49	Salivary lactoferrin is recognized by the human herpesvirus-8. <i>Journal of Investigative Dermatology</i> , 2005 , 124, 1249-58	4.3	6
48	Resistance mutations before and after tenofovir regimen failure in HIV-1 infected patients. <i>Journal of Medical Virology</i> , 2005 , 76, 297-301	19.7	15
47	Virological and pharmacological factors associated with virological response to salvage therapy after an 8-week of treatment interruption in a context of very advanced HIV disease (GigHAART ANRS 097). <i>Journal of Medical Virology</i> , 2005 , 77, 345-50	19.7	24
46	Clinically relevant genotype interpretation of resistance to didanosine. <i>Antimicrobial Agents and Chemotherapy</i> , 2005 , 49, 1739-44	5.9	58
45	Virological and pharmacological parameters predicting the response to lopinavir-ritonavir in heavily protease inhibitor-experienced patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2005 , 49, 1720-6	5.9	49
44	Didanosine in HIV-1-infected patients experiencing failure of antiretroviral therapy: a randomized placebo-controlled trial. <i>Journal of Infectious Diseases</i> , 2005 , 191, 840-7	7	45
43	Reversibility of pulmonary arterial hypertension in HIV/HHV8-associated Castleman's disease. <i>European Respiratory Journal</i> , 2005 , 26, 969-72	13.6	37
42	Comparison of tests and procedures to build clinically relevant genotypic scores: application to the Jaguar study. <i>Antiviral Therapy</i> , 2005 , 10, 479-87	1.6	8
41	Predictors of virologic response to ritonavir-boosted protease inhibitors. <i>AIDS Reviews</i> , 2005 , 7, 225-32	1.5	5
40	Comparison of Tests and Procedures to Build Clinically Relevant Genotypic Scores: Application to the Jaguar Study. <i>Antiviral Therapy</i> , 2005 , 10, 479-487	1.6	21

39	Comparison of the dynamics of resistance-associated mutations to nucleoside reverse transcriptase inhibitors, nonnucleoside reverse transcriptase inhibitors, and protease inhibitors after cessation of antiretroviral combination therapy. <i>Antimicrobial Agents and Chemotherapy</i> , 2004 , 48, 644-7	5.9	16
38	Clinically relevant interpretation of genotype and relationship to plasma drug concentrations for resistance to saquinavir-ritonavir in human immunodeficiency virus type 1 protease inhibitor-experienced patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2004 , 48, 4687-92	5.9	43
37	GENOPHAR: a randomized study of plasma drug measurements in association with genotypic resistance testing and expert advice to optimize therapy in patients failing antiretroviral therapy. <i>HIV Medicine</i> , 2004 , 5, 352-9	2.7	56
36	Fatal disseminated Kaposi's sarcoma following human herpesvirus 8 primary infections in liver-transplant recipients. <i>Liver Transplantation</i> , 2004 , 10, 295-300	4.5	54
35	Thymidine analogue reverse transcriptase inhibitors resistance mutations profiles and association to other nucleoside reverse transcriptase inhibitors resistance mutations observed in the context of virological failure. <i>Journal of Medical Virology</i> , 2004 , 72, 162-5	19.7	101
34	Resistance profiles observed in virological failures after 24 weeks of amprenavir/ritonavir containing regimen in protease inhibitor experienced patients. <i>Journal of Medical Virology</i> , 2004 , 74, 16-20	19.7	19
33	Quantification of Kaposi's sarcoma-associated herpesvirus in blood, oral mucosa, and saliva in patients with Kaposi's sarcoma. <i>AIDS Research and Human Retroviruses</i> , 2004 , 20, 704-8	1.6	31
32	Characterization of genotypic determinants in HR-1 and HR-2 gp41 domains in individuals with persistent HIV viraemia under T-20. <i>Aids</i> , 2004 , 18, 1340-2	3.5	33
31	Virologic outcome after switching from a nucleoside reverse transcriptase inhibitor to tenofovir in patients with undetectable HIV-1 RNA plasma level. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2004 , 36, 876-8	3.1	3
30	High-dose therapy plus autologous hematopoietic stem cell transplantation for human immunodeficiency virus (HIV)-related lymphoma: results and impact on HIV disease. <i>Haematologica</i> , 2004 , 89, 1100-8	6.6	64
29	Persistence of Multidrug-Resistant HIV-1 without Antiretroviral Treatment 2 Years after Sexual Transmission. <i>Antiviral Therapy</i> , 2004 , 9, 415-421	1.6	37
28	Interruption of nonnucleoside reverse transcriptase inhibitor (NNRTI) therapy for 2 months has no effect on levels of human immunodeficiency virus type 1 in plasma of patients harboring viruses with mutations associated with resistance to NNRTIs. <i>Journal of Clinical Microbiology</i> , 2003 , 41, 2713-5	9.7	13
27	Rituximab therapy for HIV-associated Castleman disease. <i>Blood</i> , 2003 , 102, 2786-8	2.2	126
26	Prevalences of herpesviruses DNA sequences in salivary gland biopsies from primary and secondary Sjögren's syndrome using degenerated consensus PCR primers. <i>Journal of Clinical Virology</i> , 2003 , 28, 165-8	14.5	12
25	Genotypic inhibitory quotient as predictor of virological response to ritonavir-amprenavir in human immunodeficiency virus type 1 protease inhibitor-experienced patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2003 , 47, 594-600	5.9	88
24	Efficacy and safety of ritonavir/indinavir 100/400 mg twice daily in combination with two nucleoside analogues in antiretroviral treatment-naïve HIV-infected individuals. <i>Antiviral Therapy</i> , 2003 , 8, 603-9	1.6	6
23	Increase of HIV-1 Pro-Viral Dna per Million Peripheral Blood Mononuclear Cells in Patients with Advanced HIV Disease (Cd4<200 Cells/Mm3) Receiving Interleukin 2 Combined with Haart Versus Haart Alone (Anrs-082 Trial). <i>Antiviral Therapy</i> , 2003 , 8, 233-237	1.6	6
22	Efficacy and Safety of Ritonavir/Indinavir 100/400 Mg Twice Daily in Combination with Two Nucleoside Analogues in Antiretroviral Treatment-Naïve HIV-Infected Individuals. <i>Antiviral Therapy</i> , 2003 , 8, 603-609	1.6	11

21	Kaposi's sarcoma herpesvirus and HIV-1 seroprevalences in prostitutes in Djibouti. <i>Journal of Medical Virology</i> , 2002 , 68, 164-7	19.7	23
20	Human immunodeficiency virus (HIV) Type 1 reverse transcriptase resistance mutations in hepatitis B virus (HBV)-HIV-coinfected patients treated for HBV chronic infection once daily with 10 milligrams of adefovir dipivoxil combined with lamivudine. <i>Antimicrobial Agents and Chemotherapy</i> , 2002 , 46, 1586-8	5.9	57
19	Kaposi's sarcoma associated with previous human herpesvirus 8 infection in heart transplant recipients. <i>Journal of Clinical Microbiology</i> , 2002 , 40, 2217-9	9.7	22
18	HIV and antiretroviral drug distribution in plasma and fat tissue of HIV-infected patients with lipodystrophy. <i>Aids</i> , 2002 , 16, 2419-24	3.5	38
17	Identification of Kaposi's sarcoma-associated herpesvirus (KSHV)-specific cytotoxic T-lymphocyte epitopes and evaluation of reconstitution of KSHV-specific responses in human immunodeficiency virus type 1-Infected patients receiving highly active antiretroviral therapy. <i>Journal of Virology</i> , 2002 , 76, 2634-40	6.6	87
16	Prospective study of the effects of antiretroviral therapy on Kaposi sarcoma-associated herpesvirus infection in patients with and without Kaposi sarcoma. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2002 , 31, 384-90	3.1	102
15	Impact of stavudine phenotype and thymidine analogues mutations on viral response to stavudine plus lamivudine in ALTIS 2 ANRS trial. <i>Antiviral Therapy</i> , 2002 , 7, 211-8	1.6	10
14	Impact of Stavudine Phenotype and Thymidine Analogues Mutations on Viral Response to Stavudine plus Lamivudine in Altis 2 Anrs Trial. <i>Antiviral Therapy</i> , 2002 , 7, 211-218	1.6	15
13	Human herpesvirus-8 seroconversions after renal transplantation. <i>Transplantation</i> , 2001 , 72, 1319-20	1.8	22
12	Clinical features and contribution of virological findings to the management of Kaposi sarcoma in organ-allograft recipients. <i>Archives of Dermatology</i> , 2000 , 136, 1452-8		44
11	Relationship between Kaposi's sarcoma, Kaposi's sarcoma-associated herpesvirus and AIDS dementia complex. <i>Aids</i> , 2000 , 14, 333-5	3.5	2
10	Primary infection with human herpesvirus 8 in an HIV-1-infected patient. <i>Aids</i> , 2000 , 14, 1471-3	3.5	3
9	Outcome of kidney transplant recipients with previous human herpesvirus-8 infection. <i>Transplantation</i> , 2000 , 69, 1776-9	1.8	74
8	Absence of a link between human herpesvirus 8 and pemphigus. <i>British Journal of Dermatology</i> , 1999 , 141, 159-60	4	16
7	Human herpesvirus 8 infection, Castleman's disease and POEMS syndrome. <i>British Journal of Haematology</i> , 1999 , 104, 932-3	4.5	25
6	Human retrovirus-5 and Sjögren's syndrome. <i>Clinical Microbiology and Infection</i> , 1999 , 5, 105-106	9.5	1
5	Lack of evidence of an association between HHV-8 and multiple myeloma. <i>Leukemia</i> , 1998 , 12, 1840-1	10.7	10
4	Prevalence of human herpesvirus 8 infection measured by antibodies to a latent nuclear antigen in patients with various dermatologic diseases. <i>Archives of Dermatology</i> , 1998 , 134, 700-2		27

- 3 HHV-8 and multiple myeloma in France. *Lancet, The*, **1997**, 350, 1144 40 68
- 2 The 501Y.V2 SARS-CoV-2 variant has an intermediate viral load between the 501Y.V1 and the historical variants in nasopharyngeal samples from newly diagnosed COVID-19 patients 3
- 1 XAV-19, a swine glyco-humanized polyclonal antibody against SARS-CoV-2 Spike receptor-binding domain, targets multiple epitopes and broadly neutralizes variants 2